IFM Therapeutics is a biopharmaceutical company. It is focused on the research and development of biological treatments for inflammatory diseases and cancer. The company's mission is to improve the lives of patients by developing small molecule drugs that target the innate immune system.
Type | Private | |
Founded | 2017 | |
HQ | Boston, MA, US | Map |
Website | ifmthera.com |
Employees (est.) (Jan 2021) | 30 | (-3%) |
Cybersecurity rating | A | More |
Founding Date | 2017 |
IFM Therapeutics total Funding | $82.5 m |
IFM Therapeutics latest funding size | $55.50 m |
Time since last funding | a year ago |
IFM Therapeutics investors | Atlas Venture, Novartis, Abingworth, Omega Funds |
IFM Therapeutics has 598 Twitter Followers. The number of followers has increased 0.5% month over month and increased 1% quarter over quarter
403
Tweets
268
Following
598
Followers
7
Tweets last 30 days
3.4
Avg. likes per Tweet
100%
Tweets with engagement
When was IFM Therapeutics founded?
IFM Therapeutics was founded in 2017.
Who are IFM Therapeutics key executives?
IFM Therapeutics's key executives are Martin Seidel, Dennis Dean and William R. Roush.
How many employees does IFM Therapeutics have?
IFM Therapeutics has 30 employees.
Who are IFM Therapeutics competitors?
Competitors of IFM Therapeutics include Xilio Therapeutics, Karo Pharma and Alligator Bioscience.
Where is IFM Therapeutics headquarters?
IFM Therapeutics headquarters is located at 855 Boylston St 11th floor, Boston.
Where are IFM Therapeutics offices?
IFM Therapeutics has an office in Boston.
How many offices does IFM Therapeutics have?
IFM Therapeutics has 1 office.
Receive alerts for 300+ data fields across thousands of companies